Autoimmunity as a predisposition for infectious diseases

PLoS Pathogens

Volumn 6, Issue 11, 2010, Pages

  Maddur, Mohan S ^a   Vani, Janakiraman ^a   Lacroix Desmazes, Sébastien ^a   Kaveri, Srinivas ^a   Bayry, Jagadeesh ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AUTOANTIBODY; AUTOIMMUNE REGULATOR PROTEIN; B CELL ACTIVATING FACTOR; GAMMA INTERFERON ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; INTERFERON ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD22; NEUTRALIZING ANTIBODY; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIMICROBIAL THERAPY; ARTICLE; AUTOIMMUNITY; BACTERIAL IMMUNITY; BACTERIAL INFECTION; CELLULAR IMMUNITY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE PREDISPOSITION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION; INFECTION RESISTANCE; INFECTION RISK; LISTERIOSIS; MYCOBACTERIOSIS; PLASMAPHERESIS; PROTEIN PHOSPHORYLATION; PSORIASIS; RHEUMATOID ARTHRITIS; VIRUS INFECTION; COMMUNICABLE DISEASE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

AUTOIMMUNITY; COMMUNICABLE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 79251501647     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001077     Document Type: Article

References (55)

1. Shoenfeld Y (1994) Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 8: 1296-1301.
2. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity-friends or foes? Trends Immunol 30: 409-414.
3. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5: 648-652.
4. Invernizzi P, Gershwin ME (2009) The genetics of human autoimmune disease. J Autoimmun 33: 290-299.
5. Hewagama A, Richardson B (2009) The genetics and epigenetics of autoimmune diseases. J Autoimmun 33: 3-11.
6. Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112: 1557-1569.
7. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057.
8. Dubin PJ, Kolls JK (2008) Th17 cytokines and mucosal immunity. Immunol Rev 226: 160-171.
9. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J (2009) Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 30: 287-295.
10. Dinarello CA (2003) Anti-cytokine therapeutics and infections. Vaccine 21 Suppl 2: S24-34.
11. Winthrop KL, Chiller T (2009) Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 5: 405-410.
12. Marodi L, Casanova JL Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies? Nat Rev Immunol 10: 299-300.
13. Madariaga L, Amurrio C, Martin G, Garcia-Cebrian F, Bicandi J, et al. (1998) Detection of anti-interferon-c autoantibodies in subjects infected by Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2: 62-68.
14. Doffinger R, Helbert MR, Barcenas-Morales G, Yang K, Dupuis S, et al. (2004) Autoantibodies to interferon-c in a patient with selective susceptibility to mycobacterial infection and organspecific autoimmunity. Clin Infect Dis 38: e10-14.
15. Hoflich C, Sabat R, Rosseau S, Temmesfeld B, Slevogt H, et al. (2004) Naturally occurring anti- IFN-c autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103: 673-675.
16. Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, et al. (2005) Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-c. J Clin Invest 115: 2480-2488.
17. Patel SY, Ding L, Brown MR, Lantz L, Gay T, et al. (2005) Anti-IFN-c autoantibodies in disseminatednontuberculous mycobacterial infections. J Immunol 175: 4769-4776.
18. Tanaka Y, Hori T, Ito K, Fujita T, Ishikawa T, et al. (2007) Disseminated Mycobacterium avium complex infection in a patient with autoantibody to interferon-c. Intern Med 46: 1005-1009.
19. Koya T, Tsubata C, Kagamu H, Koyama K, Hayashi M, et al. (2009) Anti-interferon-c autoantibody in a patient with disseminated Mycobacterium avium complex. J Infect Chemother 15: 118-122.
20. Baerlecken N, Jacobs R, Stoll M, Schmidt RE, Witte T (2009) Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-c autoantibody. Clin Infect Dis 49: e76-78.
21. Casanova JL, Abel L (2002) Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20: 581-620.
22. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, et al. (2008) Recurrent staphylococcal cellulites and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 180: 647-654.
23. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, et al. (1997) Interleukin- 6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 176: 439-444.
24. van Enckevort FH, Sweep CG, Span PN, Netea MG, Hermus AR, et al. (2001) Reduced adrenal response and increased mortality after systemic Klebsiella pneumoniae infection in interleukin-6-deficient mice. Eur Cytokine Netw 12: 581-586.
25. Cole N, Bao S, Stapleton F, Thakur A, Husband AJ, et al. (2003) Pseudomonas aeruginosa keratitis in IL-6-deficient mice. Int Arch Allergy Immunol 130: 165-172.
26. Diao H, Kohanawa M (2005) Endogenous interleukin-6 plays a crucial protective role in streptococcal toxic shock syndrome via suppression of tumor necrosis factor alpha production. Infect Immun 73: 3745-3748.
27. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, et al. (1999) Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/ macrophage colony-stimulating factor. J Exp Med 190: 875-880.
28. Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, et al. (2009) Granulocyte/macrophage- colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 113: 2547-2556.
29. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, et al. (2007) GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 356: 567-579.
30. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, et al. (2004) High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 103: 1089-1098.
31. Nakata K, Kanazawa H, Watanabe M (2006) Why does the autoantibody against granulocytemacrophage colony-stimulating factor cause lesions only in the lung? Respirology 11 Suppl: S65-S69.
32. Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, et al. (2009) Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 361: 2679-2681.
33. Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, et al. (2008) Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 205: 2703-2710.
34. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, et al. (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206: 299-311.
35. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, et al. (2009) Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5: e1000703. doi:10.1371/journal.ppat.1000703.
36. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, et al. (2010) Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207: 299-308.
37. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, et al. (2010) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207: 291-297.
38. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, et al. (2008) Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 205: 1543-1550.
39. Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, et al. (2003) Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-a, interferon- v and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 132: 128-136.
40. Zhang W, Liu JL, Meager A, Newsom-Davis J, Willcox N (2003) Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-c responses of healthy CD4+ T cells. J Neuroimmunol 139: 102-108.
41. van de Vosse E, van Dissel JT, Ottenhoff TH (2009) Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis 9: 688-698.
42. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, et al. (2009) Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 361: 1760-1767.
43. Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, et al. (2009) A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 361: 1727-1735.
44. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, et al. (2008) The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 4: e1000034. doi:10.1371/journal. ppat.1000034.
45. Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, et al. (2006) Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3: e289. doi:10.1371/journal.pmed.0030289.
46. Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6: 394-403.
47. Tedder TF (2009) CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 5: 572-577.
48. Dorner T, Radbruch A, Burmester GR (2009) Bcell- directed therapies for autoimmune disease. Nat Rev Rheumatol 5: 433-441.
49. Korhonen R, Moilanen E (2009) Anti-CD20 antibody rituximab in the treatment of rheumatoidarthritis. Basic Clin Pharmacol Toxicol 106: 13-21.
50. McDonald V, Leandro M (2009) Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 146: 233-246.
51. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755.
52. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29: 608-615.
53. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 25: 306-310.
54. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355: 1772-1779.
55. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, et al. (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-251.